Loading
A phase 3 trial of Thyrotropin alfa in Thyroid cancer, run by Genzyme, a Sanofi Company, completed.
A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen is a phase 3 interventional study registered as NCT00295763 by Genzyme, a Sanofi Company, with 61 participants recorded, started 2006-05 and reaching its primary completion in 2006-07. Interventions recorded: Thyrogen (thyrotropin alfa for injection). Conditions recorded: Differentiated Thyroid Cancer.
Linked to the drug Thyrotropin alfa because the registry names it among its interventions and Thyroid cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Thyrotropin alfa, Thyroid cancer and the tag pipeline.
Shares Thyrotropin alfa, Thyroid cancer and the tag pipeline.
Shares Sanofi and the tag pipeline.
Shares Sanofi and the tag pipeline.
Shares Sanofi and the tag pipeline.
Shares Sanofi and the tag pipeline.
Shares Sanofi and the tag pipeline.
Shares Sanofi and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/